Compare TMUS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMUS | MRK |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.2B | 268.7B |
| IPO Year | 2004 | 1994 |
| Metric | TMUS | MRK |
|---|---|---|
| Price | $196.13 | $112.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 17 |
| Target Price | ★ $256.65 | $125.59 |
| AVG Volume (30 Days) | 6.1M | ★ 7.6M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | 2.06% | ★ 3.06% |
| EPS Growth | 0.62 | ★ 8.01 |
| EPS | 2.27 | ★ 7.28 |
| Revenue | $40,604,000,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $9.27 | $3.61 |
| Revenue Next Year | $4.59 | $5.41 |
| P/E Ratio | $86.40 | ★ $15.03 |
| Revenue Growth | ★ 9.03 | 1.31 |
| 52 Week Low | $181.36 | $75.40 |
| 52 Week High | $261.50 | $125.14 |
| Indicator | TMUS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 43.28 |
| Support Level | $185.77 | $105.23 |
| Resistance Level | $204.46 | $112.44 |
| Average True Range (ATR) | 6.05 | 2.90 |
| MACD | 0.85 | -0.69 |
| Stochastic Oscillator | 57.43 | 34.39 |
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, and that firm merged with Sprint in 2020, creating the second-largest wireless carrier in the US. T-Mobile now serves 86 million postpaid and 26 million prepaid phone customers, equal to around 30% of the US retail wireless market. The firm entered the fixed-wireless broadband market aggressively in 2021 and now serves 8 million residential and business customers with its wireless network. It also serves 1 million fiber broadband customers through joint ventures with fiber network owners. T-Mobile owns a stake in these firms, which provide wholesale access to their networks. In addition, T-Mobile provides wholesale services to wireless resellers.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).